Cencora vs Amgen

Side-by-side comparison of AI visibility scores, market position, and capabilities

Amgen leads in AI visibility (88 vs 77)
Cencora logo

Cencora

LeaderHealthcare Tech

Enterprise

Conshohocken PA pharmaceutical distribution (NYSE: COR, formerly AmerisourceBergen) at $316B+ revenue; Retina Consultants of America acquisition $4.4B (Jan 2025) expanding into specialty physician care competing with McKesson.

AI VisibilityBeta
Overall Score
B77
Category Rank
#44 of 596
AI Consensus
88%
Trend
stable
Per Platform
ChatGPT
75
Perplexity
74
Gemini
76

About

Cencora, Inc. (formerly AmerisourceBergen, rebranded August 2023) is a Conshohocken, Pennsylvania-based pharmaceutical distribution and healthcare services company — publicly traded on the New York Stock Exchange (NYSE: COR) as an S&P 500 Health Care component, ranked #10 on the 2024 Fortune 500 and #24 on the Global Fortune 500 — distributing brand-name, generic, and specialty pharmaceuticals, over-the-counter products, and home healthcare supplies to 110,000+ points of care across 11 countries through 46,000+ employees and $316+ billion in annual revenue. Cencora operates as one of the "Big Three" pharmaceutical wholesalers in the United States alongside McKesson and Cardinal Health, collectively supplying approximately 90%+ of the US pharmaceutical supply chain. The company distributes from 26 US pharmaceutical distribution centers and 1,300+ locations across 50+ countries. In January 2025, Cencora completed the acquisition of approximately 85% interest in Retina Consultants of America (RCA) — a leading management services organization for retina specialists — for $4.4 billion, advancing its strategy to expand from pharmaceutical distribution into specialty physician-administered treatments and the high-growth specialty pharmaceutical services market. Founded through the 2001 merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, with predecessor companies tracing to the 1970s, Cencora adopted its current name (meaning "center, core, heart" in multiple languages) in 2023 to signal the brand's evolution beyond commodity distribution.

Full profile
Amgen logo

Amgen

LeaderHealthcare Tech

AI Drug Discovery

Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.

AI VisibilityBeta
Overall Score
A88
Category Rank
#3 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
87
Gemini
85

About

Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.

Full profile

AI Visibility Head-to-Head

77
Overall Score
88
#44
Category Rank
#3
88
AI Consensus
78
stable
Trend
stable
75
ChatGPT
83
74
Perplexity
87
76
Gemini
85
75
Claude
90
79
Grok
92

Key Details

Category
Enterprise
AI Drug Discovery
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Amgen
AI Drug Discovery

Integrations

Both integrate with
Only Cencora
Only Amgen
Cencora is classified as company. Amgen is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.